COP1 and lung carcinoma: demonstrated that decreased COP1 leads to increased accumulation of c-Jun, which subsequently inhibits HDAC3 expression, thereby enhancing histone H3 acetylation of the PD-L1 promoter and promoting the cisplatin resistance process in lung cancer cells (8).